Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Oncotarget|April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancerSaeed Rafii, Charlie Gourley, Rajiv Kumar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerGerhardt Attard, Alison H M Reid, Roger A'Hern, et al.Future Oncology (London, England)|February 5, 2014
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancerL Rhoda Molife, Aurelius Omlin, Rob J Jones, et al.Japanese Journal of Clinical Oncology|January 16, 2025
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern AsiaHsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, et al.Plos One|November 13, 2012
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancersGeraldine Perkins, Timothy A Yap, Lorna Pope, et al.Advances in Therapy|October 17, 2018
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid TumoursRuth Plummer, Henk M Verheul, Filip Y F L De Vos, et al.The Lancet. Oncology|December 7, 2020
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThomas Powles, Elizabeth R Plimack, Denis Soulières, et al.European Urology|July 27, 2023
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 StudyElizabeth R Plimack, Thomas Powles, Viktor Stus, et al.European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetateAlison H M Reid, Gerhardt Attard, Daniel C Danila, et al.Pageof 5